Last reviewed · How we verify
NCT06228807
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
trial testing The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups. in Heart Failure With Preserved Ejection Fraction in 584 participants. Completed in 30 September 2023.
30 September 2023
Quick facts
| Lead sponsor | Ya-Wei Xu |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 584 |
| Start date | 9 March 2015 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 September 2023 |
Drugs / interventions tested
- The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.
Conditions studied
- Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →
Sponsor
Ya-Wei Xu — full company profile →
Who can join
18 and older, any sex, with Heart Failure With Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heart failure with preserved ejection fraction (HFpEF) is a prevalent form of heart failure characterized by impaired left ventricle pressures and diastolic dysfunction. Despite its increasing prevalence, effective treatment options for HFpEF remain limited, probably due to its heterogenous underlying pathological etiology involving chronic systemic inflammation and metabolic dysregulation. Identifying new predictors of poor prognosis is crucial for risk stratification and tailored management.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.
Mohammed AQ, Luo Y, Chen Y, Alifu J, et al · · 2025 · cited 2× · PMID 40855570 · DOI 10.1186/s12967-025-06964-8
Verify or expand the search:
- PubMed search for NCT06228807
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Preserved Ejection Fraction
Currently open trials in the same condition.
- NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati · NA · recruiting
- NCT06937827 — Transitions of Care Clinic (TOCC) · NA · recruiting
- NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
- NCT06702501 — The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF) · NA · recruiting
- NCT06616974 — A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction · Phase 2 · recruiting
Other Ya-Wei Xu trials
Trials by the same sponsor.
- NCT06690684 — Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases · enrolling by invitation
- NCT05935436 — Cardiac Shock Wave Therapy for the Treatment of Myocardial Infarction With Non-obstructive Coronary Arteries · NA · unknown
- NCT05354128 — Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak. · NA · unknown
- NCT06385782 — Exploring HRV in Antarctic Overwintering Members of Asia · completed
- NCT03802929 — Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06228807 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ya-Wei Xu
- Last refreshed: 2 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06228807.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing